Marina N. Magrey

Jun 24, 2024 | mdedge.com | Marina N. Magrey

Nonradiographic axial spondyloarthritis (nr-axSpA) shares many characteristics with radiographic disease and responds to the same treatments, yet it has fewer FDA-approved options. As Dr Marina Magrey, from Case Western Reserve University School of Medicine, in Cleveland, Ohio, explains, the TNF inhibitor certolizumab has been approved on the basis of results from the C-axSpAnd study.

Oct 4, 2023 | ard.bmj.com | Xenofon Baraliakos |Atul Deodhar |Marina N. Magrey |Walter P. Maksymowych

Safety data for the DBTP have been reported previously and are summarised in table 3.22 At Week 52, ≥1 TEAE was reported for 183 out of 244 (75.0%; EAIR/100 PY: 202.1) patients with nr-axSpA and 249 out of 330 (75.5%; EAIR/100 PY: 200.8) with r-axSpA who had received ≥1 dose of BKZ (table 3).